151 related articles for article (PubMed ID: 37803102)
1. The impact of changes in gadolinium-enhancement on disease progression in children with neurofibromatosis type 1-associated optic pathway glioma: a retrospective analysis.
Kotch C; Si SJ; Desai K; Caminada P; Lo Russo FM; Li Y; Liu GT; Avery RA; Fisher MJ
J Neurooncol; 2023 Sep; 164(3):741-747. PubMed ID: 37803102
[TBL] [Abstract][Full Text] [Related]
2. Tumor load rather than contrast enhancement is associated with the visual function of children and adolescents with optic pathway glioma - a retrospective Magnetic Resonance Imaging study.
Kilian A; Aigner A; Simon M; Salchow DJ; Potratz C; Thomale UW; Hernáiz Driever P; Tietze A
J Neurooncol; 2022 Feb; 156(3):589-597. PubMed ID: 34994964
[TBL] [Abstract][Full Text] [Related]
3. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort.
Falzon K; Drimtzias E; Picton S; Simmons I
Br J Ophthalmol; 2018 Oct; 102(10):1367-1371. PubMed ID: 29343527
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.
Kotch C; Avery R; Getz KD; Bouffet E; de Blank P; Listernick R; Gutmann DH; Bornhorst M; Campen C; Liu GT; Aplenc R; Li Y; Fisher MJ
Neuro Oncol; 2022 Aug; 24(8):1377-1386. PubMed ID: 35018469
[TBL] [Abstract][Full Text] [Related]
5. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
6. Quantitative MRI demonstrates abnormalities of the third ventricle subventricular zone in neurofibromatosis type-1 and sporadic paediatric optic pathway glioma.
Boonzaier NR; Hales PW; D'Arco F; Walters BC; Kaur R; Mankad K; Cooper J; Liasis A; Smith V; O'Hare P; Hargrave D; Clark CA
Neuroimage Clin; 2020; 28():102447. PubMed ID: 33038669
[TBL] [Abstract][Full Text] [Related]
7. Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort.
Blanchard G; Lafforgue MP; Lion-François L; Kemlin I; Rodriguez D; Castelnau P; Carneiro M; Meyer P; Rivier F; Barbarot S; Chaix Y;
Eur J Paediatr Neurol; 2016 Mar; 20(2):275-281. PubMed ID: 26774135
[TBL] [Abstract][Full Text] [Related]
8. The Utility of Early Brain MRI for Patients with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Long-Term Follow-Up in a Tertiary Referral Hospital.
Rony C; Aharoni S; Halevy A
Neuropediatrics; 2022 Oct; 53(5):370-375. PubMed ID: 35381604
[TBL] [Abstract][Full Text] [Related]
9. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
Fisher MJ; Loguidice M; Gutmann DH; Listernick R; Ferner RE; Ullrich NJ; Packer RJ; Tabori U; Hoffman RO; Ardern-Holmes SL; Hummel TR; Hargrave DR; Bouffet E; Charrow J; Bilaniuk LT; Balcer LJ; Liu GT
Neuro Oncol; 2012 Jun; 14(6):790-7. PubMed ID: 22474213
[TBL] [Abstract][Full Text] [Related]
10. Surveillance magnetic resonance imaging for isolated optic pathway gliomas: is gadolinium necessary?
Maloney E; Stanescu AL; Perez FA; Iyer RS; Otto RK; Leary S; Steuten L; Phipps AI; Shaw DWW
Pediatr Radiol; 2018 Sep; 48(10):1472-1484. PubMed ID: 29789890
[TBL] [Abstract][Full Text] [Related]
11. Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center study.
Henning AM; Handrup MM; Kjeldsen SM; Larsen DA; Ejerskov C
Orphanet J Rare Dis; 2021 Nov; 16(1):489. PubMed ID: 34809690
[TBL] [Abstract][Full Text] [Related]
12. Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients.
Pinheiro SL; Maciel J; Cavaco D; Figueiredo AA; Damásio IL; Donato S; Passos J; Simões-Pereira J
Hormones (Athens); 2023 Mar; 22(1):79-85. PubMed ID: 36269545
[TBL] [Abstract][Full Text] [Related]
13. Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1.
Trevisson E; Cassina M; Opocher E; Vicenzi V; Lucchetta M; Parrozzani R; Miglionico G; Mardari R; Viscardi E; Midena E; Clementi M
J Neurooncol; 2017 Sep; 134(2):279-287. PubMed ID: 28577031
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone excess in children with neurofibromatosis type-1 and optic glioma.
Cambiaso P; Galassi S; Palmiero M; Mastronuzzi A; Del Bufalo F; Capolino R; Cacchione A; Buonuomo PS; Gonfiantini MV; Bartuli A; Cappa M; Macchiaiolo M
Am J Med Genet A; 2017 Sep; 173(9):2353-2358. PubMed ID: 28631895
[TBL] [Abstract][Full Text] [Related]
15. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program.
Dalla Via P; Opocher E; Pinello ML; Calderone M; Viscardi E; Clementi M; Battistella PA; Laverda AM; Da Dalt L; Perilongo G
Neuro Oncol; 2007 Oct; 9(4):430-7. PubMed ID: 17704361
[TBL] [Abstract][Full Text] [Related]
16. Neurofibromatosis Type 1-Associated Optic Pathway Glioma in Children: A Follow-Up of 10 Years or More.
Kinori M; Armarnik S; Listernick R; Charrow J; Zeid JL
Am J Ophthalmol; 2021 Jan; 221():91-96. PubMed ID: 32283094
[TBL] [Abstract][Full Text] [Related]
17. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
18. Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1.
Avery RA; Mansoor A; Idrees R; Trimboli-Heidler C; Ishikawa H; Packer RJ; Linguraru MG
Neurology; 2016 Dec; 87(23):2403-2407. PubMed ID: 27815398
[TBL] [Abstract][Full Text] [Related]
19. Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.
de Blank PM; Berman JI; Liu GT; Roberts TP; Fisher MJ
Neuro Oncol; 2013 Aug; 15(8):1088-95. PubMed ID: 23658320
[TBL] [Abstract][Full Text] [Related]
20. NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat.
Azizi AA; Walker DA; Liu JF; Sehested A; Jaspan T; Pemp B; Simmons I; Ferner R; Grill J; Hargrave D; Driever PH; Evans DG; Opocher E;
Neuro Oncol; 2021 Jan; 23(1):100-111. PubMed ID: 32628746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]